Pillar Biosciences Appoints Todd Christian and Yann Echelard, Ph.D., to Its Board of Directors
Appointments follow the latest strategic financing to support joint NGS automation strategies and advance IVD development and commercialization NATICK, Mass. — September 3, 2026 — Pillar Biosciences, a global manufacturer and provider of next-generation sequencing (NGS) kitted solutions, today announced the appointments of Todd Christian and Yann Echelard, Ph.D., to its Board of Directors. The appointments were […]
Pillar Biosciences and Hamilton Expand Automated NGS Library Preparation Method for oncoReveal® Nexus 21 Gene Panel on Hamilton Microlab STAR™ and STARlet™ Liquid Handling Systems
NATICK, MA. and RENO, NV – August 27, 2026 – Pillar Biosciences, Inc., and Hamilton Company today announced the validation and commercial release of the latest automated NGS library preparation method under their NGS Application Development and Co-Marketing Agreement for the on Hamilton Microlab® STAR™and STARlet™ liquid handling systems. This latest milestone expands the growing […]
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Announce Liquid Biopsy Screening Collaboration in Lung Cancer
oncoReveal® Essential+ validated at LSI Medience for cfDNA/cfRNA screening in the LC-SCRUM-Asia project, with testing planned to begin in August 2026 NATICK, Mass. and TOKYO, Japan – August 19, 2026 – Pillar Biosciences, Inc. (“Pillar”), LC-SCRUM-Asia and LSI Medience Corporation (“LSI Medience”) today announced a collaboration to support genomic screening of blood-based samples from patients […]
CellCarta and Pillar Biosciences Accelerate FGFR NGS Assay from RUO to IUO for Global Phase 3 Oncology Trial
Integrated collaboration completed clinical trial assay development and validation and enabled IDE and associated regulatory submissions in approximately five to six months. MONTREAL, CANADA, – June 23, 2026 – CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced the successful development and clinical implementation of a customized FGFR next-generation sequencing assay in collaboration […]
CellCarta and Pillar Biosciences Announce Multi-Year Global Strategic Partnership to Expand Rapid, Decentralized Tumor Profiling for Oncology Clinical Trials
The partnership pairs Pillar’s portfolio of oncoReveal® kitted NGS panels with CellCarta’s global laboratory network and biomarker expertise to reduce screening friction, improve turnaround time, reduce failure rates, and support scalable companion diagnostic programs. MONTREAL, QC and ANTWERP, BELGIUM / NATICK, MA – April 2, 2026 – CellCarta, a global provider of precision medicine laboratory […]
Pillar Biosciences Launches oncoReveal® Rapid AML Panel to Support Rapid, Guideline‑Informed Genomic Insights for Acute Myeloid Leukemia
NATICK, MA — March 3, 2026 — Pillar Biosciences today announced the launch of the oncoReveal® Rapid AML Panel, a focused research-use-only (RUO) DNA next-generation sequencing (NGS) panel designed to help laboratories generate key acute myeloid leukemia (AML) genomic results more efficiently. AML is an aggressive hematologic malignancy where molecular characterization can be time-sensitive in […]
Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China
NATICK, Mass. – December 8, 2025 – (PR NEWSWIRE) – Pillar Biosciences announced today an expansion of its existing laboratory access program with AstraZeneca for NGS-based kitted liquid biopsy tumor profiling to include China. This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local […]
Pillar Biosciences Announces Final CMS Pricing Determination for oncoReveal® CDx
Natick, Mass. – December 1, 2025 – Pillar Biosciences, the leader in Decision Medicine™, todayannounced that the Centers for Medicare & Medicaid Services (CMS) has finalized its pricingdetermination for oncoReveal CDx. Following its preliminary decision in August 2025, CMSconfirmed a crosswalk-based payment rate of $1,352.09, effective for claims with dates of service onor after January […]
Pillar Biosciences Announce Automated NGS Library Preparation Method on Hamilton Microlab STAR to Accelerate Myeloproliferative Neoplasm Research
NATICK, Mass. and RENO, NV – October 28, 2025 Pillar Biosciences, Inc., and Hamilton Company today announced the validation and release of their first automated NGS library preparation method under their NGS Application Development and Co-Marketing Agreement, for use on Hamilton Microlab® STARTM liquid handling systems. Pillar’s research-use-only (RUO) oncoReveal® Essential MPN, a rapid 3-gene […]
Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting
NATICK, Mass. – October 23, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston, MA. The company and scientific collaborators will collectively present eight studies and host three corporate workshops, showcasing their latest advancements in rapid Next-Generation Sequencing (NGS) […]